Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated? #ACR20 @RheumNow

@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group

FAST trial: allopurinol vs febuxostat on safety (for gout pts on allopurinol, with ≥1 CV RF, TTT dosing) febuxostat non-inferior for CV events Well, that's a relief. gout flare similar, good follow-up, colchicine did not influence out in Lancet today? #ACR20 ABSTL08 @RheumNow https://t.co/5LeXV5mgu9

Results of the FAST trial presented at #ACR20 - Safety study required by the EMA - Febuxostat non-inferior to allopurinol for any outcomes - Long-term use of febuxostat is not associated with an increased risk of death Published in @TheLancet today https://t.co/EvJGPpDCR8

• DEFINE_ME

Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovascular events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat @rheumnow #ACR20 Abstr#L08 #ACRbest

FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2

• https://meet.acrconvergence.org/meetings/bFG6BTawj43DP9SbX

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Rituximab in AAV: how to dose? Should we be giving: - 'haem dosing': 375mg/m2 x4 doses - 'RA dosing': 1000mg x2 doses Systematic review says: no difference Reassuring given the variation in practice in real life! #ACR20 ABST2048 @RheumNow https://t.co/Jf4Ue6HRRL

Anakinra in #Stills disease - Double blind, placebo controlled RCT in Stills disease total 12pts, 6 placebo, 6 Rx grp. All pts reached ACR70 at week 2 without fever and sustained it at 12 weeks. 5/6 reached ACR90 @RheumNow #ACR20 ABS#1633 #ACRbest https://t.co/9E4vm7WzhP

Wonder if you can predict which pts you can successfully taper off bDMARDs? Abst#1538 from Denmark showed that a neg IgM-RF (OR 0.26) & low Doppler serum score for 24 jts predicted successful discontinuation of bDMARDs at 2yr f/u in RA pts w/ DAS28-CRP<2.6. #ACR20 @RheumNow https://t.co/CbJTguxaoa

I am glad now that chloroquine is not available (permanent back order) in Canada as results of high retinal toxicity w chloroquine was sobering & changed my practice. I won’t use it long term @RheumNow #ACR20 @CRASCRRheum abstr#1825 https://t.co/1RQi41uV1B https://t.co/lc9za22Zw1

• https://twitter.com/aliduartemd/status/1325817215095103488

We need to work together with our patients to ensure medication adherence during this pandemic. 1⃣30% of 734 pts on DMARDs changed their med use during COVID 2⃣Med change without physician guidance 3⃣Changes resulted in ⬆️steroid use @RheumNow #ACR20 Abs#L05 https://t.co/n18zqed4wC